Patents by Inventor Andrew T. Watt

Andrew T. Watt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of ribonuclease L expression
    Publication number: 20030100522
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ribonuclease L. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ribonuclease L. Methods of using these compounds for modulation of ribonuclease L expression and for treatment of diseases associated with expression of ribonuclease L are provided.
    Type: Application
    Filed: September 12, 2001
    Publication date: May 29, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of complement component C3 expression
    Publication number: 20030096775
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of complement component C3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding complement component C3. Methods of using these compounds for modulation of complement component C3 expression and for treatment of diseases associated with expression of complement component C3 are provided.
    Type: Application
    Filed: October 23, 2001
    Publication date: May 22, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Mark J. Graham, Andrew T. Watt
  • Antisense modulation of hormone-sensitive lipase expression
    Publication number: 20030096771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hormone-sensitive lipase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hormone-sensitive lipase. Methods of using these compounds for modulation of hormone-sensitive lipase expression and for treatment of diseases associated with expression of hormone-sensitive lipase are provided.
    Type: Application
    Filed: July 26, 2001
    Publication date: May 22, 2003
    Inventors: Madeline M. Butler, Andrew T. Watt, Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of Interferon gamma receptor 1 expression
    Patent number: 6566132
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 1. Methods of using these compounds for modulation of Interferon gamma receptor 1 expression and for treatment of diseases associated with expression of Interferon gamma receptor 1 are provided.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: May 20, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of caspase 6 expression
    Patent number: 6566135
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of caspase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 6. Methods of using these compounds for modulation of caspase 6 expression and for treatment of diseases associated with expression of caspase 6 are provided.
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: May 20, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of vascular endothelial growth factor receptor-2 expression
    Publication number: 20030092649
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of vascular endothelial growth factor receptor-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vascular endothelial growth factor receptor-2. Methods of using these compounds for modulation of vascular endothelial growth factor receptor-2 expression and for treatment of diseases associated with expression of vascular endothelial growth factor receptor-2 are provided.
    Type: Application
    Filed: September 28, 2001
    Publication date: May 15, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of caspase 9 expression
    Publication number: 20030087871
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of caspase 9. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 9. Methods of using these compounds for modulation of caspase 9 expression and for treatment of diseases associated with expression of caspase 9 are provided.
    Type: Application
    Filed: October 15, 2002
    Publication date: May 8, 2003
    Inventors: Hong Zhang, Andrew T. Watt
  • Antisense modulation of protein kinase R expression
    Publication number: 20030087855
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.
    Type: Application
    Filed: September 13, 2001
    Publication date: May 8, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of RECQL5 expression
    Publication number: 20030083302
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL5. Methods of using these compounds for modulation of RECQL5 expression and for treatment of diseases associated with expression of RECQL5 are provided.
    Type: Application
    Filed: September 9, 2002
    Publication date: May 1, 2003
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of raidd expression
    Patent number: 6551826
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RAIDD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RAIDD. Methods of using these compounds for modulation of RAIDD expression and for treatment of diseases associated with expression of RAIDD are provided.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: April 22, 2003
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of dual specific phosphatase 5 expression
    Publication number: 20030060437
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of diseases associated with expression of dual specific phosphatase 5 are provided.
    Type: Application
    Filed: May 25, 2001
    Publication date: March 27, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Andrew T. Watt
  • Antisense modulation of caspase 9 expression
    Patent number: 6492170
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of caspase 9. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 9. Methods of using these compounds for modulation of caspase 9 expression and for treatment of diseases associated with expression of caspase 9 are provided.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: December 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of Apaf-1 expression
    Patent number: 6468795
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Apaf-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Apaf-1. Methods of using these compounds for modulation of Apaf-1 expression and for treatment of diseases associated with expression of Apaf-1 are provided.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: October 22, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • Antisense modulation of bifunctional apoptosis regulator expression
    Patent number: 6468796
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of bifunctional apoptosis regulator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bifunctional apoptosis regulator. Methods of using these compounds for modulation of bifunctional apoptosis regulator expression and for treatment of diseases associated with expression of bifunctional apoptosis regulator are provided.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: October 22, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Andrew T. Watt
  • ANTISENSE INHIBITOR OF RECQL4 EXPRESSION
    Publication number: 20020142975
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL4. Methods of using these compounds for modulation of RECQL4 expression and for treatment of diseases associated with expression of RECQL4 are provided.
    Type: Application
    Filed: February 23, 2001
    Publication date: October 3, 2002
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of WRN expression
    Patent number: 6448080
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of WRN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding WRN. Methods of using these compounds for modulation of WRN expression and for treatment of diseases associated with expression of WRN are provided.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of helicase-moi expression
    Patent number: 6444466
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: September 3, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense inhibitor of RECQL4 expression
    Patent number: 6436706
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL4. Methods of using these compounds for modulation of RECQL4 expression and for treatment of diseases associated with expression of RECQL4 are provided.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: August 20, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of tumor necrosis factor receptor 2 expression
    Patent number: 6410324
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Tumor Necrosis Factor Receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Tumor Necrosis Factor Receptor 2. Methods of using these compounds for modulation of Tumor Necrosis Factor Receptor 2 expression and for treatment of diseases associated with expression of Tumor Necrosis Factor Receptor 2 are provided.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: June 25, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Andrew T. Watt
  • Antisense modulation of phospholipase A2, group VI (Ca2+-independent) expression
    Patent number: 6410325
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group VI (Ca2+-independent). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group VI (Ca2+-independent). Methods of using these compounds for modulation of Phospholipase A2, group VI (Ca2+-independent) expression and for treatment of diseases associated with expression of Phospholipase A2, group VI (Ca2+-independent) are provided.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: June 25, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Andrew T. Watt